MYCN Amplification in RB1‐Inactivated Retinoblastoma: Association With High‐Risk Features
Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.ABSTRACT Background MYCN amplification occurs in a subset of retinoblastoma cases, both with and without RB1 inactivation. It has been suggested that retinoblastomas with MYCN amplification represent a distinct entity with more aggressive clinical behavior.
Kyriaki Papaioannou +9 more
wiley +1 more source
Choroidal Metastasis as Initial Presentation in Adenocarcinoma of Lung: A Case Report [PDF]
Journal of Clinical and Diagnostic Research, 2017 Vision impairment as an initial presentation detecting choroid metastasis in primary lung cancer is rare. Prevention or treatment of visual loss and improvement in quality of life can be achieved by treatment of intraocular metastasis.
SAROJ KUMAR DAS +4 more
doaj +1 more source
Expression and prognostic value of putative cancer stem cell markers CD117 and CD15 in choroidal and ciliary body melanoma [PDF]
, 2015 AIMS: The aim of the present study was to immunohistochemically investigate the expression and prognostic significance of putative cancer stem cell markers CD117 (c-kit), CD34, CD20 and CD15 in a cohort of patients with primary choroidal and ciliary ...
Dotlić, Snježana +5 more
core +1 more source
Survival impact of second primary cutaneous and non‐cutaneous melanoma in melanoma survivors
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 823-834, May 2026.In this US population‐based cohort study, melanoma survivors diagnosed with regional/distant‐stage SPCM or SPNCM had worse survival compared to those with a single melanoma. Abstract Background Melanoma survivors have a high risk of developing second primary neoplasms, both cutaneous melanoma (SPCM) and non‐cutaneous melanoma (SPNCM), but little is ...
Jingjing Xie +3 more
wiley +1 more source
Characterization of Luteinizing hormone-releasing hormone (LH-RH-I) receptor type I as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines [PDF]
, 2019 K
Dobos, Nikoletta +8 more
core +1 more source
Intraocular Metastasis: Differential Diagnosis and Management
Clinical &Experimental Ophthalmology, Volume 54, Issue 3, Page 382-397, April 2026.ABSTRACT Intraocular metastases represent the most common type of malignant intraocular tumour in adults. These commonly affect the choroid but can also involve the iris, ciliary body, retina, vitreous, optic disc or lens. Breast and lung cancer are the most common origins of intraocular metastases.
Genovefa Μachairoudia +3 more
wiley +1 more source
Application of Multimodal and Molecular Imaging Techniques in the Detection of Choroidal Melanomas
Frontiers in Oncology, 2021 Choroidal melanomas are the most common ocular malignant tumors worldwide. The onset of such tumors is insidious, such that affected patients often have no pain or obvious discomfort during early stages. Notably, enucleation is required for patients with
Xuying Li +5 more
doaj +1 more source
Uveal melanoma: Therapeutic consequences of doubling times and irradiation results; a review [PDF]
, 1992 Thirty-six of 39 published calculated doubling times (Td's) of uveal melanomas appeared to be longer than 60 days. Metastatic death occurs 35–40 Td's after dissemination.
Manschot, W.A., Strik, R. (Roel) van
core +1 more source
BMEMat, Volume 4, Issue 1, March 2026.Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen +7 more
wiley +1 more source
Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma. [PDF]
, 2017 Uveal melanoma is the most common primary intraocular malignant tumor in adults and arises from the transformation of melanocytes in the uveal tract. Even after treatment of the primary tumor, up to 50% of patients succumb to metastatic disease.
Aplin, Andrew E. +5 more
core +1 more source